Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial

Circulation. 2020 Jul 28;142(4):419-421. doi: 10.1161/CIRCULATIONAHA.120.046320. Epub 2020 Jul 27.

Affiliations

¹ Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.
² Department of Radiology, Johns Hopkins University School of Medicine (H.L.), Baltimore, Maryland.
³ Mallinckrodt Institute of Radiology, Division of Nuclear Medicine, Washington University School of Medicine, Washington University in St. Louis, MO (T.H.S.).

No abstract available

Keywords: acute coronary syndrome; cholesterol, LDL; evolocumab; secondary prevention.

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Anticholesteremic Agents / pharmacology
Anticholesteremic Agents / therapeutic use*
Apolipoproteins B / blood
Biomarkers*
Cholesterol, HDL / blood
Cholesterol, LDL
Humans
Lipoproteins / blood*
Myocardial Infarction / blood*
Myocardial Infarction / drug therapy*
Myocardial Infarction / etiology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Apolipoproteins B
Biomarkers
Cholesterol, HDL
Cholesterol, LDL
Lipoproteins
evolocumab

Grants and funding

P30 AI094189/AI/NIAID NIH HHS/United States